在台灣，隨著人口的老化，中老年人的泌尿系統疾病也日益增多，泌尿科的重要性也不斷增加。目前在台灣泌尿科醫療服務體系主要提供者包括診所、綜合醫院以及醫學中心，其中專業的泌尿專科醫院非常少見。目前國內對泌尿科專科醫院的經營與管理策略的研究還相對缺乏，為一個值得深入探討的重要領域。
本研究首先透過文獻回顧、市場分析來探討泌尿專科的醫療市場現況和發展趨勢，再經由問卷訪談與實例分析，規劃出理想中的泌尿專科醫院構想。 泌尿專科醫院的經營策略制定則是利用SWOT分析與波士頓矩陣 (BCG Matrix)分析。
理想中的泌尿科專科醫院，應立基於醫學中心水準的醫療核心能力，具備先進的微創醫療手術設備，提供從泌尿疾病的健檢、保健，到個人化醫療、VIP高端醫療的全人照護。服務的客源不是僅限於局部地區，國際醫療也將是重要目標之一。另外，泌尿專科醫院也可以承擔教學與研究的任務，並成為泌尿科創新醫療的研發、臨床試驗中心。泌尿專科醫院應該針對SWOT分析結果制定因應的經營策略。根據健保署泌尿科前十大疾病與實例前20常見住院疾病與臨床療效資料，本研究界定出泌尿科專科醫院應致力提供的主要醫療服務產品，利用BCG矩陣分析進一步將這些主要醫療服務分類為金牛產品、問題產品、明星產品和老狗產品，並制定針對性的經營策略。男性賀爾蒙低下症（男性更年期）與糖尿病、代謝症候群、胰島素抗性、肥胖、勃起功能障礙顯著相關；代謝症候群會增加尿路結石發生的機率，勃起功能障礙可為系統性心血管疾病的先行指標，這些均可以提供泌尿科介入的機會，進行創新跨領域的整合，如與內分泌科醫師、心臟科醫師開設共同照護門診，早期介入，共同治療，提升病人整體健康。此外，本研究也提出利用基因學的方法應用於泌尿科常見疾病的風險評估，找到罹患疾病的高風險族群，進行早期篩檢或早期診斷，這些生物指標，也可應用於精準選擇藥物，作為疾病預後的指標，以達到精準醫療的目標。
透過完整的規劃與經營策略，泌尿專科醫院可提供泌尿科患者從疾病篩檢、精準診斷、尖端醫療與創新治療，以先進、整合、全面的醫療照護達到個人化、精準醫療的目標，泌尿專科醫院將在泌尿科醫療照護中扮演重要角色。

In Taiwan, with the aging population, the incidence of urological diseases among middle-aged and elderly individuals is increasing, thus elevating the importance of urology. Currently, the main providers of urology medical services in Taiwan include clinics, general hospitals, and medical centers, with specialized urology hospitals being very rare. There is a relative lack of research on the management strategies for specialized urology hospitals domestically, making it an important area for in-depth exploration.
This study first explores the current status and development trends of the urology medical market through literature review and market analysis. Then, through questionnaire interviews and case analyses, it plans the ideal concept of a specialized urology hospital. The management strategies for specialized urology hospitals are formulated using SWOT analysis and the Boston Consulting Group (BCG) Matrix.
An ideal specialized urology hospital should be based on the medical core capabilities of a medical center, equipped with advanced minimally invasive surgical equipment, and provide comprehensive care ranging from urological disease screening and health care to personalized medical and VIP high-end medical services. The target clientele should not be limited to local areas; international medical services will also be a key objective. Additionally, specialized urology hospitals can undertake teaching and research tasks and become centers for innovative urological medical research and clinical trials. Management strategies should be formulated based on the results of the SWOT analysis. Using data from the National Health Insurance Administration on the top ten urological diseases and the top 20 common inpatient diseases and clinical efficacy, this study identifies the primary medical service products that specialized urology hospitals should focus on. Using the BCG Matrix analysis, these primary medical services are further classified into Cash Cow products, Question Mark products, Star products, and Dog products, with targeted management strategies formulated accordingly. Conditions such as male hormone deficiency (Andropause) are significantly associated with diabetes, metabolic syndrome, insulin resistance, obesity, and erectile dysfunction. Metabolic syndrome increases the risk of urinary stones, and erectile dysfunction can be an early indicator of systemic cardiovascular disease, providing opportunities for urological interventions through innovative cross-disciplinary integration, such as joint clinics with endocrinologists and cardiologists for early intervention and joint treatment to improve overall patient health. This study also proposes the use of genomics for risk assessment of common urological diseases, identifying high-risk groups for early screening or diagnosis. These biomarkers can also be used for precise medication selection and as indicators for disease prognosis to achieve the goal of precision medicine.
Through comprehensive planning and management strategies, specialized urology hospitals can provide urology patients with services ranging from disease screening, precise diagnosis, advanced medical treatment, and innovative therapies. By offering advanced, integrated, and comprehensive medical care, they can achieve the goals of personalized and precision medicine, playing a crucial role in urological medical care.

論文審定書 i
誌謝 ii
摘要 iii
Abstract v
目錄 viii
圖目錄 ix
表目錄 xi
第一章 緒論 1
第一節 研究背景與動機 1
第二節 研究目的 2
第三節 研究流程與架構 3
第二章 文獻探討 4
第一節 國內文獻探討 4
第二節 國外泌尿專科醫院的現況 5
第三節 小結 10
第三章 研究設計 11
第一節 訪談大綱 11
第二節 分析工具 14
第四章 泌尿科產業概況分析 17
第一節 泌尿科醫療範圍簡述 17
第二節 泌尿科醫療市場現況 18
第五章 分析與結果 38
第一節 訪談結果概要 38
第二節 SWOT分析 42
第三節 波士頓矩陣分析 52
第四節 泌尿專科醫院預防保健、疾病篩檢策略分析 84
第六章 結論與建議 91
參考文獻 98

一、 英文文獻
Altok, M., Demirel, C., Kang, H. C., Choi, H., John, D., Inguillo, I. A., Davis, J. W., & Ward, J. F. (2021). Impact of MRI/US fusion-guided prostate biopsy on biopsy-naïve patients: A single urologist's experience. BJUI compass, 3(1), 19–25. https://doi.org/10.1002/bco2.86
Benelli, A., Vaccaro, C., Guzzo, S., Nedbal, C., Varca, V., & Gregori, A. (2020). The role of MRI/TRUS fusion biopsy in the diagnosis of clinically significant prostate cancer. Therapeutic advances in urology, 12, 1756287220916613. https://doi.org/10.1177/1756287220916613
Berg, W. T., & Miner, M. (2020). Hypogonadism and metabolic syndrome: Review and update. Current Opinion in Endocrinology, Diabetes and Obesity, 27(6), 404-410.
Bocchino, A. C., Pezzoli, M., Martínez-Salamanca, J. I., Russo, G. I., Giudice, A. L., & Cocci, A. (2023). Low-intensity extracorporeal shock wave therapy for erectile dysfunction: Myths and realities. Investigative and clinical urology, 64(2), 118.
Chang, C. W., Tang, T. Y., Geng, J. H., Jhan, J. H., Wang, H. S., Shen, J. T., & Lee, Y. C. (2022). The safety and efficacy of vela laser en-bloc endoscopic resection versus conventional transurethral resection of bladder tumor—a single center experience. Journal of Clinical Medicine, 11(17), 5233.
Chen, L. C., Huang, S. P., Shih, C. T., Li, C. Y., Chen, Y. T., Huang, C. Y., ... & Bao, B. Y. (2023). ATP8B1: A prognostic prostate cancer biomarker identified via genetic analysis. The Prostate, 83(6), 602-611.
Cordeiro, E. R., Barwari, K., Anastasiadis, A., García, M., Branco, F., De la Rosette, J. J., & Laguna, M. P. (2013). Laparoscopic cryotherapy for small renal masses: Current State. Archivos Espanoles de Urologia, 66(1), 41-53.
Curtin, G., Scanlon, L., O'Kelly, J., Sweeney, P., & Hennessey, D. B. (2023). The decline in transurethral resection of the prostate gland in Irish public hospitals between 2005 and 2021. The Surgeon, 21(6), e346-e351.
Diaconu, C. C., Manea, M., Marcu, D. R., Socea, B., Spinu, A. D., & Bratu, O. G. (2020). The erectile dysfunction as a marker of cardiovascular disease: a review. Acta Cardiologica, 75(4), 286-292.
Dixon, C., Cedano, E. R., Pacik, D., Vit, V., Varga, G., Wagrell, L., ... & Larson, T. (2015). Efficacy and safety of Rezūm system water vapor treatment for lower urinary tract symptoms secondary to benign prostatic hyperplasia. Urology, 86(5), 1042-1047.
Egan, K. B. (2016). The epidemiology of benign prostatic hyperplasia associated with lower urinary tract symptoms: prevalence and incident rates. Urologic Clinics, 43(3), 289-297.
Elterman, D. S., Bhattacharyya, S. K., Mafilios, M., Woodward, E., Nitschelm, K., & Burnett, A. L. (2021). The quality of life and economic burden of erectile dysfunction. Research and Reports in Urology, 79-86.
Feiertag, J. H., & Clark, J. Y. (2024). National Trends in Surgical Management for Benign Prostatic Hyperplasia from 2013 to 2019 in the United States. Urology Practice, 10-1097.
Franco, J. V., Tesolin, P., & Jung, J. H. (2023). Update on the management of benign prostatic hyperplasia and the role of minimally invasive procedures. Prostate international, 11(1), 1-7.
Gandaglia, G., Briganti, A., Jackson, G., Kloner, R. A., Montorsi, F., Montorsi, P., & Vlachopoulos, C. (2014). A systematic review of the association between erectile dysfunction and cardiovascular disease. European urology, 65(5), 968-978.
Heers, H., & Turney, B. W. (2016). Trends in urological stone disease: a 5‐year update of hospital episode statistics. BJU international, 118(5), 785-789.
Helms, M. M., & Nixon, J. (2010). Journal of Strategy and Management. Journal of Strategy and Management, 3(3), 215-251.
Ho, C. Y., Lee, J. I., Huang, S. P., Chen, S. C., & Geng, J. H. (2023). A Genome-Wide Association Study of Metabolic Syndrome in the Taiwanese Population. Nutrients, 16(1), 77.
Huang, S. P., Chen, L. C., Chen, Y. T., Lee, C. H., Huang, C. Y., Yu, C. C., ... & Bao, B. Y. (2021). PTBP1 genetic variants affect the clinical response to androgen-deprivation therapy in patients with prostate cancer. Cancer Genomics & Proteomics, 18(3), 325-334.
Kader, M. A., & Hossain, H. (2020). An analysis on BCG growth sharing matrix. International Journal of Economics, Business and Accounting Research (IJEBAR), 4(01).
Kasivisvanathan, V., Rannikko, A. S., Borghi, M., Panebianco, V., Mynderse, L. A., Vaarala, M. H., ... & Moore, C. M. (2018). MRI-targeted or standard biopsy for prostate-cancer diagnosis. New England Journal of Medicine, 378(19), 1767-1777.
Kaufmann, B., Raess, E., Schmid, F. A., Bieri, U., Scherer, T. P., Elleisy, M., ... & Eberli, D. (2024). Focal therapy with high‐intensity focused ultrasound for prostate cancer: 3‐year outcomes from a prospective trial. BJU international, 133(4), 413-424.
Kessler, A., Sollie, S., Challacombe, B., Briggs, K., & Van Hemelrijck, M. (2019). The global prevalence of erectile dysfunction: a review. BJU international, 124(4), 587-599.
Kirlangic, O. F., Yilmaz-Oral, D., Kaya-Sezginer, E., Toktanis, G., Tezgelen, A. S., Sen, E., ... & Gur, S. (2020). The effects of androgens on cardiometabolic syndrome: current therapeutic concepts. Sexual Medicine, 8(2), 132-155
Kirlangic, O. F., Yilmaz-Oral, D., Kaya-Sezginer, E., Toktanis, G., Tezgelen, A. S., Sen, E., ... & Gur, S. (2020). The effects of androgens on cardiometabolic syndrome: current therapeutic concepts. Sexual Medicine, 8(2), 132-155.
Launer, B. M., McVary, K. T., Ricke, W. A., & Lloyd, G. L. (2021). The rising worldwide impact of benign prostatic hyperplasia. BJU international, 127(6), 722-728.
Lee, Y. H., Huang, W. C., Tsai, J. Y., Lu, C. M., Chen, W. C., Lee, M. H., ... & Chang, L. S. (2002). Epidemiological studies on the prevalence of upper urinary calculi in Taiwan. Urologia internationalis, 68(3), 172-177.
Leong, J. Y., Tokarski, A. T., Roehrborn, C. G., & Das, A. K. (2021). UroLift and Rezum: minimally invasive surgical therapies for the management of benign prostatic hyperplasia. Can J Urol, 28(S2), 2-5.
Liu, C. C., Lee, Y. C., Huang, S. P., Cheng, K. H., Hsieh, T. J., Huang, T. Y., ... & Wu, W. J. (2018). Hepatocyte nuclear factor-4α P2 promoter variants are associated with the risk of metabolic syndrome and testosterone deficiency in aging Taiwanese men. The Journal of Sexual Medicine, 15(11), 1527-1536.
Liu, D., Li, C., Li, Y., Zhou, L., Li, J., Wang, Y., ... & Wang, L. (2023). Benign prostatic hyperplasia burden comparison between China and United States based on the Global Burden of Disease Study 2019. World Journal of Urology, 41(12), 3629-3634.
Lu, Z., Lin, G., Reed-Maldonado, A., Wang, C., Lee, Y. C., & Lue, T. F. (2017). Low-intensity extracorporeal shock wave treatment improves erectile function: a systematic review and meta-analysis. European urology, 71(2), 223-233.
Madendere, S., Değer, M. D., & Aktoz, T. (2022). Global web trends analysis of minimally invasive urinary stone treatment in the last decade and during the COVID-19 pandemic. Journal of Endourology, 36(10), 1271-1276.
Madersbacher, S., Roehrborn, C. G., & Oelke, M. (2020). The role of novel minimally invasive treatments for lower urinary tract symptoms associated with benign prostatic hyperplasia. BJU international, 126(3), 317-326.
McVary, K. T., Gange, S. N., Shore, N. D., Bolton, D. M., Cowan, B. E., Thomas Brown, B., ... & Roehrborn, C. G. (2014). Treatment of LUTS secondary to BPH while preserving sexual function: randomized controlled study of prostatic urethral lift. The journal of sexual medicine, 11(1), 279-287.
McVary, K. T., Rogers, T., & Roehrborn, C. G. (2019). Rezūm water vapor thermal therapy for lower urinary tract symptoms associated with benign prostatic hyperplasia: 4-year results from randomized controlled study. Urology, 126, 171-179.
Minafra, P., Carbonara, U., Vitarelli, A., Lucarelli, G., Battaglia, M., & Ditonno, P. (2021). Robotic radical perineal prostatectomy: tradition and evolution in the robotic era. Current Opinion in Urology, 31(1), 11-17.
Mouraviev, V., Joniau, S., Van Poppel, H., & Polascik, T. J. (2007). Current status of minimally invasive ablative techniques in the treatment of small renal tumours. European urology, 51(2), 328-336.
Patel, R. M., & Bariol, S. (2019). National trends in surgical therapy for benign prostatic hyperplasia in Australia. ANZ Journal of Surgery, 89(4), 345-349.
Roehrborn CG, Barkin J, Gange SN, Shore ND, Giddens JL, Bolton DM, Cowan BE, Cantwell AL, McVary KT, Te AE, Gholami SS, Moseley WG, Chin PT, Dowling WT, Freedman SJ, Incze PF, Coffield KS, Herron S, Rashid P, Rukstalis DB.(2017). Five year results of the prospective randomized controlled prostatic urethral L.I.F.T. study. Can J Urol. 2017 Jun;24(3):8802-8813. PMID: 28646935.
Sciacqua, L. V., Vanzulli, A., Di Meo, R., Pellegrino, G., Lavorato, R., Vitale, G., & Carrafiello, G. (2023). Minimally Invasive Treatment in Benign Prostatic Hyperplasia (BPH). Technology in cancer research & treatment, 22, 15330338231155000. https://doi.org/10.1177/15330338231155000
Sønksen, J., Barber, N. J., Speakman, M. J., Berges, R., Wetterauer, U., Greene, D., ... & Gratzke, C. (2015). Prospective, randomized, multinational study of prostatic urethral lift versus transurethral resection of the prostate: 12-month results from the BPH6 study. European urology, 68(4), 643-652.
Sorokin, I., Mamoulakis, C., Miyazawa, K., Rodgers, A., Talati, J., & Lotan, Y. (2017). Epidemiology of stone disease across the world. World journal of urology, 35, 1301-1320.
Stabilini, C., van Veenendaal, N., Aasvang, E., Agresta, F., Aufenacker, T., Berrevoet, F., ... & Simons, M. (2023). Update of the international HerniaSurge guidelines for groin hernia management. BJS open, 7(5), zrad080.
Traish, A. M., Guay, A., Feeley, R., & Saad, F. (2009). The dark side of testosterone deficiency: I. Metabolic syndrome and erectile dysfunction. Journal of andrology, 30(1), 10-22.
Traish, A. M., Guay, A., Feeley, R., & Saad, F. (2009). The dark side of testosterone deficiency: I. Metabolic syndrome and erectile dysfunction. Journal of andrology, 30(1), 23-32.
Traish, A. M., Saad, F., Feeley, R. J., & Guay, A. (2009). The dark side of testosterone deficiency: III. Cardiovascular disease. Journal of andrology, 30(5), 477-494.
Tzelves, L., Türk, C., & Skolarikos, A. (2021). European association of urology urolithiasis guidelines: where are we going?. European Urology Focus, 7(1), 34-38.
Venkatramani, V. (2015). Urovision 2020: The future of urology. Indian Journal of Urology, 31(2), 150-155.
von Hardenberg, J., Westhoff, N., Baumunk, D., Hausmann, D., Martini, T., Marx, A., ... & Ritter, M. (2018, September). Prostate cancer treatment by the latest focal HIFU device with MRI/TRUS-fusion control biopsies: A prospective evaluation. In Urologic Oncology: Seminars and Original Investigations (Vol. 36, No. 9, pp. 401-e1). Elsevier.
Wang, L., Lu, B., He, M., Wang, Y., Wang, Z., & Du, L. (2022). Prostate cancer incidence and mortality: global status and temporal trends in 89 countries from 2000 to 2019. Frontiers in public health, 10, 811044.
Westhoff, N., Ernst, R., Kowalewski, K. F., Derigs, F., Neuberger, M., Nörenberg, D., ... & von Hardenberg, J. (2023). Medium-term oncological efficacy and patient-reported outcomes after focal high-intensity focused ultrasound: the FOXPRO trial. European Urology Focus, 9(2), 283-290.
Yu, C. C., Chen, L. C., Lin, W. H., Lin, V. C., Huang, C. Y., Lu, T. L., ... & Bao, B. Y. (2020). Genetic association analysis of cell cycle regulators reveals YWHAZ has prognostic significance in prostate cancer. Cancer Genomics & Proteomics, 17(2), 209-216.
Yu, H., Isaacson, A. J., & Burke, C. T. (2016, September). Review of current literature for prostatic artery embolization. In Seminars in Interventional Radiology (Vol. 33, No. 03, pp. 231-235). Thieme Medical Publishers.
Zhu, C., Wang, D. Q., Zi, H., Huang, Q., Gu, J. M., Li, L. Y., ... & Zeng, X. T. (2021). Epidemiological trends of urinary tract infections, urolithiasis and benign prostatic hyperplasia in 203 countries and territories from 1990 to 2019. Military Medical Research, 8, 1-12.
Ziglioli, F., Baciarello, M., Maspero, G., Bellini, V., Bocchialini, T., Cavalieri, D., ... & Maestroni, U. (2020). Oncologic outcome, side effects and comorbidity of high-intensity focused ultrasound (HIFU) for localized prostate cancer. A review. Annals of Medicine and Surgery, 56, 110-115.
二、 中文文獻
陳銘樹（2016）。醫療產業策略管理 (Health Care Industry Strategy Management)。華杏出版股份有限公司。
黃崇哲（2012）。醫療機構的經營理念與策略。華杏出版股份有限公司。
黃書彬（2021）。核磁共振奥超音波影像融合攝護腺切片 (Fusion Biopsy)。高醫醫訊，41，3。
江博暉（2022年8月21日）。專科醫院的未來。Special Forum 4: 醫學中心訓練後泌尿科醫師之出路，高雄市，台灣。
石崇良（2023年8月19日）。健康政策改革藍圖、打造全人照護體系。TUA Symposium A:健康政策與管理/產官學研之實務應用，台北市，台灣。
黃懷恩（2008）。泌尿專科醫療市場之研究-以揚昇泌尿健康中心為例。中央大學管理學院高階主管企管碩士班學位論文，2008，1-108。
三、 網路資料
Detailed Market research Methodology (2023). Urology Devices Market By Product(Dialysis Products, Urology Catheters, Other), By Disease(Benign Prostatic Hyperplasia (BPH), Prostate Cancer, Others), By End-User(Hospitals & Clinics, Dialysis Centers, Others), By Region And Companies - Industry Segment Outlook, Market Assessment, Competition Scenario, Trends, And Forecast 2023-2032. Retrieved from: https://marketresearch.biz/report/urology-devices-market/
Florida Urology Center. Retrieved from: https://www.floridaurology.com/about-florida-urology
Market Research Guru (2023). Urology Market | Expected To Be the Fastest Growing Industry 2030. Retrieved from: https://www.marketresearchguru.com
Sabah Al Ahmad Urology Centre. Retrieved from: https://www.falghanim.com/business- spectrum/construction/sabah-al-ahmad-urology-centre/
Urology Center of Alabama. Retrieved from: https://www.urologycentersalabama.com/
Urology Center of IOWA. Retrieved from: https://www.iowauro.com/
衛生福利部中央健康保險署健保統計專區。取自：https://www.nhi.gov.tw/ch/np-2993- 1.html